Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
暂无分享,去创建一个
Luca Biasco | Alessandro Aiuti | Alessandro Ambrosi | Fulvio Mavilio | Clelia Di Serio | C. Di Serio | L. Biasco | M. Roncarolo | C. Bordignon | F. Mavilio | A. Aiuti | A. Ambrosi | C. Valacca | B. Cassani | M. Mirolo | Maria Grazia Roncarolo | Claudio Bordignon | Alessandra Recchia | D. Sartori | A. Recchia | Daniela Sartori | Barbara Cassani | M. Aker | S. Scaramuzza | G. Andolfi | S. Slavin | Fabrizia Urbinati | Samantha Scaramuzza | Shimon Slavin | Grazia Andolfi | Massimiliano Mirolo | Cristina Valacca | Memet Aker | Matteo Cazzola | F. Urbinati | M. Cazzola
[1] N. Copeland,et al. Gene Therapy Insertional Mutagenesis Insights , 2004, Science.
[2] B. Kerem,et al. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy , 2006, Gene Therapy.
[3] F. Deist,et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.
[4] C. von Kalle,et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. , 2005, Blood.
[5] Takeshi Suzuki,et al. New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.
[6] A. Fischer,et al. Gene therapy for severe combined immunodeficiency: are we there yet? , 2007, The Journal of clinical investigation.
[7] A. Schambach,et al. Gene therapy: X-SCID transgene leukaemogenicity , 2006, Nature.
[8] Bruce Aronow,et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.
[9] F. Bushman,et al. Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.
[10] M. Roncarolo,et al. Therapeutic applications for hematopoietic stem cell gene transfer , 2002, Nature Immunology.
[11] A. Mortellaro,et al. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.
[12] L. Notarangelo,et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.
[13] C. von Kalle,et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. , 2005, Blood.
[14] B. Fehse,et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. , 2006, Human gene therapy.
[15] C. Bordignon,et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[16] Clelia Di Serio,et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.
[17] B. Nadel,et al. V(D)J-mediated Translocations in Lymphoid Neoplasms , 2002, The Journal of experimental medicine.
[18] Shawn M. Burgess,et al. Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.
[19] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[20] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[21] Christof von Kalle,et al. Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells , 2004, PLoS biology.
[22] T. Lu,et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[23] Alessandro Aiuti,et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. , 2007, Blood.
[24] A. Hotz-Wagenblatt,et al. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] Christine Kinnon,et al. Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.
[26] B. Fehse,et al. Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.
[27] M. Reinders,et al. Gene therapy: Is IL2RG oncogenic in T-cell development? , 2006, Nature.
[28] I. Verma,et al. Gene therapy: Therapeutic gene causing lymphoma , 2006, Nature.
[29] Cameron S. Osborne,et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.
[30] N. Copeland,et al. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. , 2005, Blood.
[31] J. Tisdale,et al. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. , 2000, Blood.
[32] E. Medico,et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. , 2005, Blood.
[33] T. Rabbitts,et al. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. , 2004, The New England journal of medicine.
[34] Sridhar Hannenhalli,et al. Genome-wide analysis of retroviral DNA integration , 2005, Nature Reviews Microbiology.
[35] M. Hershfield,et al. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. , 1998, Seminars in hematology.
[36] B. Aronow,et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates , 2003, Nature Medicine.
[37] Evelina Mazzolari,et al. Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.